Portfolio Companies 2026 for Novartis Venture Fund: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.
Novartis Venture Fund accounts for 36 tracked companies with verified cap-table data, 36 of which disclose round sizes totalling $4.7B. The median disclosed raise is $100M, and the largest is Merus at $500M, ahead of Catalym ($319M) and Atalanta Therapeutics ($262M).
The names that recur most often on these portfolio cap tables are Novartis Venture Fund (36 companies), Forbion (9 companies), Omega Funds (6 companies), Pfizer Ventures (6 companies), Versant Ventures (5 companies), M Ventures (4 companies). By latest disclosed round, the market skews Series A (15), Series B (13), Series D (3), IPO (2).
Companies tracked: 36
Disclosed funding total: $4.7B across 36 companies
Median disclosed raise: $100M
Largest raise: Merus — $500M
Stage mix: Series A 15 · Series B 13 · Series D 3 · IPO 2
